Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Plans Reverse Stock Split to Acquire Cequent, Changes Name

Premium

MDRNA said this week that its acquisition of Cequent Pharmaceuticals will go forward following a shareholder vote on the issue, and that it has also changed its name to Marina Biotech.

According to Marina, it will enact a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the deal.

"The primary objective of the reverse split was to allow us to issue additional shares for the shareholder approved acquisition of Cequent," Marina CFO Peter Garcia said in a statement.

Earlier this year, MDRNA announced it would acquire Cequent for $46 million in stock (GSN 4/1/2010).

"The acquisition of Cequent is a critical cornerstone of our RNAi roll-up strategy," President and CEO Michael French added. "As Marina Biotech, we will have two complementary and proprietary RNAi drug discovery platforms."

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.